Inhibitory effect of UDP-glucose on cAMP generation and insulin secretion

Fariborz Parandeh1, Stefan Amisten1, Gaurav Verma1

  • 1Department of Clinical Science, Division of Islet Cell Physiology, UMAS University of Lund, Malmö, Sweden.

Insights

UDP-glucose (UDP-G) activates P2Y14 receptors, suppressing insulin secretion in type-2 diabetes (T2D). This study reveals UDP-G

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Metabolic Diseases

Background:

  • Type-2 diabetes (T2D) is characterized by impaired pancreatic beta-cell insulin secretion.
  • The precise molecular mechanisms causing beta-cell dysfunction in T2D remain incompletely understood.
  • UDP-glucose (UDP-G) and its receptor P2Y14 are implicated in cellular signaling pathways.

Purpose of the Study:

  • To investigate the role of UDP-glucose (UDP-G) and its specific receptor P2Y14 in regulating insulin secretion from pancreatic beta-cells.
  • To elucidate the molecular mechanisms by which UDP-G affects beta-cell function and viability in the context of type-2 diabetes.

Main Methods:

  • Utilized human isolated pancreatic islets and INS-1 cells for experiments.
  • Assessed glucose-stimulated insulin secretion (GSIS) following P2Y14 activation with UDP-G.
  • Employed pertussis-toxin (PTX) pretreatment and P2Y14 knockdown to investigate signaling pathways.
  • Measured intracellular cAMP levels, cellular reductive capacity, cell viability, and apoptosis.
  • Examined the impact of UDP-G on glucose-induced proliferation of INS-1 cells.

Main Results:

  • P2Y14 is expressed in human and rodent pancreatic beta-cells.
  • UDP-G activation of P2Y14 dose-dependently suppressed GSIS; P2Y14 knockdown abolished this effect.
  • Pertussis-toxin (PTX) pretreatment improved GSIS and blocked UDP-G's inhibitory action.
  • UDP-G-induced suppression of GSIS correlated with reduced cAMP levels.
  • UDP-G diminished beta-cell reductive capacity and exacerbated glucose-induced cell death and apoptosis.
  • These detrimental effects were counteracted by a cAMP analog.
  • UDP-G modulated glucose-induced proliferation in INS-1 cells.

Conclusions:

  • P2Y14 receptor activation by UDP-glucose plays a significant role in suppressing insulin secretion.
  • UDP-G negatively impacts pancreatic beta-cell function and viability, potentially contributing to T2D pathogenesis.
  • Targeting the P2Y14/UDP-G pathway may offer a novel therapeutic strategy for T2D.

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
5.9K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.9K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.7K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
436
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
434
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
6.3K